Eplerenone
Brand names: Eplerenone, Inspra
At a glance
- Medicare prescriptions, 2024
- 167,980
- Medicare drug cost
- $13.1M
- Average cost per prescription
- $77.69
- Clinicians who prescribed it
- 7,112
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Cardiology 34.1%
- Nurse Practitioners 13.1%
- Internal Medicine 11.6%
- Nephrology (Kidney) 9.6%
- Heart Failure & Transplant Cardiology 9.5%
- Interventional Cardiology 7.9%
- Family Medicine 4.9%
- Physician Assistants 3.9%
- Cardiac Electrophysiology 1.3%
- Endocrinology & Diabetes 1.0%
- Geriatric Medicine 0.5%
- Nuclear Medicine 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 58% from 2019 to 2024.
Biggest change by state since 2019
- Massachusetts +92%
- Michigan +74%
- Texas +68%
- Ohio +68%
- Illinois +57%
- New Jersey (smallest change) +24%
- Florida (smallest change) +40%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Accord Healthcare, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow diamond tablet, 7 mm | E1 |
| 50 mg | yellow diamond tablet, 9 mm | E2 |
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow diamond tablet, 7 mm | E 25 |
Breckenridge Pharmaceutical, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow diamond tablet, 7 mm | E 25 |
| 50 mg | yellow diamond tablet, 9 mm | E 50 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow diamond tablet, 7 mm | E1 |
Viatris Specialty LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 25 mg | yellow diamond tablet, 7 mm | VLE NSR 25 |
| 50 mg | yellow diamond tablet, 9 mm | VLE NSR 50 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.